Cell-Wall Polysaccharide Immunoactivator for Humoral and Cellular Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunoactivators lack the ability to effectively enhance both humoral and cellular immunity while ensuring safety and efficacy, particularly in the context of natural product-derived substances.
Innovation Solution
Development of particles with a diameter of 1 to 800 nm comprising cell-wall-derived polysaccharides from sources like licorice, yeast, and lactic acid bacteria, which can be administered via various routes to induce both types of immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunoactivators are used to enhance immune function, then immune activation efficacy is improved, but safety concerns and limited ability to induce both humoral and cellular immunity simultaneously occur
Solution Approach 1:
The patent changes the particle size parameter to 1-800 nm and specifies polysaccharide composition from natural sources, which transforms the immune response profile to simultaneously induce both humoral and cellular immunity while improving safety tolerability
Solution Approach 2:
The patent uses composite polysaccharide particles derived from natural sources (yeast, lactic acid bacteria, plants) that combine multiple beneficial properties: immunogenicity, safety, and the ability to activate both arms of the immune system
2Object-affected harmful factors
If natural product-derived substances are used as immunoactivators, then safety perception is improved, but efficacy in inducing both humoral and cellular immunity is insufficient
Solution Approach 1:
The patent specifies critical parameters including particle size (1-800 nm) and polysaccharide composition that enable natural product-derived substances to simultaneously achieve high safety perception and dual immunity induction capability
Data Source
AI summary
Disclosed is an immunoactivator that is capable of enhancing induction of both humoral immunity and cellular immunity and contains an active ingredient derived from cell walls (derived from a natural product); a vaccine adjuvant; and a method for inducing immunity including administering the immunoactivator. Theimmunoactivator contains, as an active ingredient, particles having a maximum diameter within a range of 1 to 800 nm, wherein the particles comprise cell-wall-derived polysaccharides.